Form 4: Avalo Therapeutics Director Jonathan Goldman Reports Stock Transaction
SEC Form 4 Filing
Director Jonathan Goldman reports the vesting of restricted stock units into common stock of Avalo Therapeutics.
Summary
- On March 28, 2025, Jonathan Goldman, a director of Avalo Therapeutics, Inc., had 3,167 restricted stock units vest into common stock.
- This transaction is reported on a Form 4 filing with the SEC.
- Following the transaction, Goldman directly owns 6,333 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions, neither particularly positive nor negative.
Industry Context
This is a standard SEC filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in the director's holdings.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Reporting Person was granted 9,500 restricted stock units |
| 03/28/2025 | 3,167 restricted stock units vested |
| 03/28/2025 | Date of transaction |
| 04/01/2025 | Date of report |
| 03/28/2026 | Next vesting date for restricted stock units |
| 03/28/2027 | Final vesting date for restricted stock units |
Keywords
Form 4, Avalo Therapeutics, Director, Jonathan Goldman, Restricted Stock Units, Common Stock, Vesting, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.